(EVOK) Evoke Pharma - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30049G2030
EVOK: Nasal Spray, Gastroparesis Drug
Evoke Pharma, Inc. (NASDAQ:EVOK) is a specialty pharmaceutical company dedicated to addressing unmet medical needs in gastroenterology. Its lead product, Gimoti, is a nasal spray formulation of metoclopramide, approved for the treatment of acute and recurrent diabetic gastroparesis in adults. This innovative delivery method addresses challenges associated with oral administration, particularly in patients with delayed gastric emptying. The companys strategic focus is on targeting gastroenterologists, internal medicine specialists, and primary care physicians, ensuring precise delivery of its therapy to the appropriate patient population. Incorporated in 2007 and headquartered in Solana Beach, California, Evoke Pharma operates with a specialized approach to commercialization, emphasizing education and outreach within the medical community to improve awareness and treatment of diabetic gastroparesis.
Based on the provided data, Evoke Pharmas stock (NASDAQ:EVOK) is currently trading at $3.70, below its 20-day SMA of $4.61 and 50-day SMA of $4.60. The 200-day SMA stands at $5.13, indicating a downward trend over the past year. The Average True Range (ATR) of 0.36 suggests moderate volatility. Fundamental analysis highlights a market cap of $6.01M and a P/S ratio of 0.70, signaling a low valuation relative to its revenue. The P/B ratio of 1.34 reflects a reasonable valuation relative to book value. Over the next three months, the stock may experience continued pressure due to its position below key moving averages. However, any positive developments in revenue growth or operational efficiency could provide upside potential. The stocks small market cap and moderate volatility make it sensitive to broader market conditions and company-specific news.
Additional Sources for EVOK Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EVOK Stock Overview
Market Cap in USD | 6m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2013-09-25 |
EVOK Stock Ratings
Growth 5y | -93.8% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -53.2 |
Analysts | 4/5 |
Fair Price Momentum | 1.90 USD |
Fair Price DCF | - |
EVOK Dividends
No Dividends PaidEVOK Growth Ratios
Growth Correlation 3m | -15.8% |
Growth Correlation 12m | -71.7% |
Growth Correlation 5y | -96.8% |
CAGR 5y | -50.53% |
CAGR/Max DD 5y | -0.51 |
Sharpe Ratio 12m | -1.37 |
Alpha | -67.51 |
Beta | 1.62 |
Volatility | 98.83% |
Current Volume | 25.3k |
Average Volume 20d | 9.3k |
As of March 15, 2025, the stock is trading at USD 3.82 with a total of 25,299 shares traded.
Over the past week, the price has changed by -1.55%, over one month by -28.86%, over three months by -16.75% and over the past year by -52.81%.
No, based on ValueRay Analyses, Evoke Pharma (NASDAQ:EVOK) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -93.83 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EVOK as of March 2025 is 1.90. This means that EVOK is currently overvalued and has a potential downside of -50.26%.
Evoke Pharma has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy EVOK.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, EVOK Evoke Pharma will be worth about 2.1 in March 2026. The stock is currently trading at 3.82. This means that the stock has a potential downside of -46.34%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 18 | 371.2% |
Analysts Target Price | 18 | 371.2% |
ValueRay Target Price | 2.1 | -46.3% |